Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma.
There is increasing evidence for a role of pulmonary surfactant in asthma and allergic inflammation. In murine asthma models, recent studies have demonstrated that surfactant components downregulate the allergic inflammation. Therefore, we tested the hypothesis that in individuals with mild asthma, a natural porcine surfactant preparation (Curosurf) given before segmental allergen challenge can reduce the allergic airway inflammation. Ten patients with asthma and five healthy control subjects were treated in two segments with either Curosurf or vehicle followed by local allergen challenge. Six additional patients with asthma received Curosurf before allergen challenge in one segment as above, but the second segment was instilled with Curosurf without allergen challenge. Unexpectedly, surfactant treatment augmented the eosinophilic inflammation 24 hours after allergen challenge. A direct chemotactic effect of Curosurf was excluded. However, levels of eotaxin and interleukin-5 were increased in bronchoalveolar lavage after Curosurf treatment, whereas IFN-gamma-levels and numbers of IFN-gamma(+) T cells were decreased. Curosurf had no influence on spreading and retention of allergen determined by allergen uptake in mice. These findings demonstrate that treatment with a natural porcine surfactant results in an augmentation of the eosinophilic inflammation after allergen challenge that is more likely due to immunomodulatory effects than to biophysical properties of the surfactant.
Erpenbeck
Veit J
VJ
Fraunhofer Institute of Toxicology and Experimental Medicine, Germany.
Hagenberg
Andreas
A
Dulkys
Yasmin
Y
Elsner
Jörn
J
Bälder
Ralf
R
Krentel
Harald
H
Discher
Marc
M
Braun
Armin
A
Krug
Norbert
N
Hohlfeld
Jens M
JM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000485:Allergens / Q000009:adverse effects / Q000276:immunology; D001249:Asthma / Q000276:immunology*; D001688:Biological Products / Q000009:adverse effects* / Q000276:immunology; D016535:Bronchial Hyperreactivity / Q000276:immunology; D001985:Bronchial Provocation Tests; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000276:immunology; D016022:Case-Control Studies; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000032:analysis / Q000276:immunology; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007249:Inflammation; D007371:Interferon-gamma / Q000032:analysis / Q000187:drug effects / Q000276:immunology; D015848:Interleukin-5 / Q000032:analysis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000009:adverse effects* / Q000276:immunology; D054397:Receptors, CCR3; D019713:Receptors, CCR5 / Q000032:analysis / Q000187:drug effects / Q000276:immunology; D019707:Receptors, Chemokine / Q000032:analysis / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000485:Allergens; D001688:Biological Products; C515456:CCL11 protein, human; C515350:CCR3 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D015848:Interleukin-5; D010743:Phospholipids; D054397:Receptors, CCR3; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D007371:Interferon-gamma; C068291:poractant alfa